Edgestream Partners L.P. Purchases 10,482 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Edgestream Partners L.P. lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 10.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,883 shares of the company's stock after purchasing an additional 10,482 shares during the period. Edgestream Partners L.P. owned about 0.09% of Apellis Pharmaceuticals worth $3,506,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in APLS. Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals in the third quarter worth about $27,000. True Wealth Design LLC purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. Capital Performance Advisors LLP purchased a new stake in Apellis Pharmaceuticals in the 3rd quarter worth about $56,000. KBC Group NV raised its stake in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after acquiring an additional 679 shares during the period. Finally, US Bancorp DE raised its stake in Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after acquiring an additional 1,327 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Stock Down 0.5 %

APLS traded down $0.12 during midday trading on Tuesday, reaching $25.02. The company's stock had a trading volume of 203,893 shares, compared to its average volume of 1,917,522. The stock's 50-day moving average is $28.94 and its 200-day moving average is $30.91. Apellis Pharmaceuticals, Inc. has a 1 year low of $23.77 and a 1 year high of $63.07. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of -12.32 and a beta of 0.92. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Remove Ads

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $212.50 million for the quarter, compared to analysts' expectations of $197.92 million. During the same period in the prior year, the firm posted ($0.73) earnings per share. The company's quarterly revenue was up 45.2% on a year-over-year basis. As a group, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on APLS shares. Royal Bank of Canada lowered their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. The Goldman Sachs Group cut their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, Wedbush dropped their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $45.53.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now directly owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO James George Chopas sold 1,096 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the transaction, the chief accounting officer now directly owns 48,138 shares in the company, valued at approximately $1,464,839.34. The trade was a 2.23 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,934 shares of company stock valued at $1,950,261. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).